세계의 홍역, 유행성이하선염, 풍진 백신 시장 예측(-2032년) : 제품, 백신 유형, 투여 경로, 연령층, 유통 채널, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Measles, Mumps, Rubella (MMR) Vaccines Market is accounted for $5.73 billion in 2025 and is expected to reach $13.83 billion by 2032 growing at a CAGR of 13.4% during the forecast period. The Measles, Mumps, Rubella (MMR) vaccine is a combined immunization that shields individuals from three serious infectious diseases: measles, mumps, and rubella. By activating the immune response, it equips the body to resist these viruses, reducing risks of severe complications like brain swelling, respiratory infections, and birth defects. Administered primarily in childhood, MMR vaccination is a cornerstone of public health, helping achieve herd immunity and preventing widespread disease transmission worldwide.

According to WHO, measles cases surged by over 79% globally in 2023 compared to the previous year, with over 306,000 reported cases and a growing trend in vaccine hesitancy worsening the situation.

Market Dynamics:

Driver:

Increasing awareness about vaccine-preventable diseases

Governments and NGOs are leveraging digital platforms and community-based programs to promote immunization schedules. The integration of mobile health apps and AI-driven reminders is improving vaccine compliance across diverse populations. As misinformation is countered with evidence-based messaging, parental confidence in routine immunizations is rising. Emerging economies are witnessing a surge in school-based vaccination drives, supported by international funding. This growing consciousness is directly translating into higher uptake of MMR vaccines across both pediatric and adult cohorts.

Restraint:

Adverse effects and safety concerns

Media amplification of rare adverse events has led to vaccine hesitancy in certain regions. Regulatory bodies are tightening pharmacovigilance protocols and mandating real-time safety monitoring through digital health records. Manufacturers are investing in formulation improvements to reduce reactogenicity and enhance tolerability. The rise of anti-vaccine sentiment on social media platforms is prompting stricter content moderation and targeted counter-campaigns. These safety-related apprehensions may slow market expansion in sensitive demographics.

Opportunity:

Rising demand for booster immunizations

As immunity wanes over time, booster doses for MMR are gaining traction among adolescents and adults. Health authorities are revising immunization guidelines to include periodic boosters, especially in outbreak-prone zones. Technological advancements in vaccine delivery-such as microneedle patches and intranasal formulations-are improving patient experience and compliance. Employers and universities are increasingly mandating booster shots, creating new institutional demand. Digital health platforms are enabling personalized vaccine tracking and automated scheduling for follow-up doses. This evolving landscape presents a lucrative opportunity for manufacturers to expand product portfolios and distribution networks.

Threat:

Competition from alternative vaccines

Innovations in recombinant and mRNA-based formulations are drawing attention for their enhanced efficacy and faster production cycles. Some regions are adopting tailored immunization strategies that prioritize disease-specific vaccines over broad-spectrum ones. Strategic partnerships between biotech firms and public health agencies are accelerating the development of next-gen alternatives. As cold-chain logistics improve, previously inaccessible vaccines are entering mainstream distribution. Without continuous innovation and differentiation, traditional MMR products risk losing market share to these emerging contenders.

Covid-19 Impact

Lockdowns and healthcare resource reallocation delayed pediatric visits and vaccine administration. However, the crisis also underscored the importance of immunization, prompting renewed investment in vaccine infrastructure. Governments introduced catch-up campaigns and digital tracking systems to recover lost ground. Telehealth platforms and mobile clinics emerged as vital tools for vaccine outreach during restricted mobility. Post-Covid strategies now emphasize resilient supply chains, decentralized delivery models, and integration of MMR vaccines into broader pandemic preparedness frameworks.

The combination vaccines segment is expected to be the largest during the forecast period

The combination vaccines segment is expected to account for the largest market share during the forecast period, due to its convenience and broad-spectrum protection. These formulations reduce the number of injections required, improving compliance among children and caregivers. Technological enhancements in antigen stabilization and adjuvant systems are boosting immunogenicity. Pediatricians prefer combination vaccines for their efficiency in clinical workflows and reduced appointment frequency. Regulatory approvals for newer multi-antigen combinations are expanding the segment's reach. As healthcare systems prioritize integrated immunization schedules, combination vaccines are set to maintain their leadership position.

The pediatric clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatric clinics segment is predicted to witness the highest growth rate. These facilities are increasingly equipped with digital immunization records and automated scheduling systems. Rising birth rates and improved access to primary care are driving footfall in pediatric settings. Clinics are adopting mobile outreach and community engagement models to reach underserved populations. Integration of AI-based diagnostic tools is enhancing early detection and timely vaccination. With growing emphasis on preventive care, pediatric clinics are becoming central nodes in the immunization ecosystem.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by expanding healthcare infrastructure and population density. Countries like India, China, and Indonesia are scaling up national immunization programs with international support. Mobile health units and digital registries are improving vaccine access in remote areas. Regional governments are investing in local manufacturing to reduce dependency on imports. Public-private partnerships are accelerating cold-chain development and last-mile delivery.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological innovation and proactive healthcare policies. The U.S. and Canada are integrating AI and IoT into vaccine distribution and monitoring systems. Regulatory agencies are streamlining approvals for advanced formulations and delivery mechanisms. Telemedicine platforms are expanding vaccine outreach beyond traditional clinics. High public health spending and insurance coverage are supporting widespread adoption. As personalized immunization strategies gain traction, North America continues to set benchmarks for global vaccine deployment.

Key players in the market

Some of the key players profiled in the Measles, Mumps, Rubella (MMR) Vaccines Market include Merck & Co., Inc., Indian Immunologicals Ltd., GlaxoSmithKline plc (GSK), Meiji Seika Pharma Co., Ltd., Sanofi, Panacea Biotec Ltd., Serum Institute of India Pvt. Ltd., LG Chem Ltd., Bharat Biotech International Ltd., Walvax Biotechnology Co., Ltd., Zydus Lifesciences Ltd., Mitsubishi Tanabe Pharma Corporation, Bio-Med Pvt. Ltd., IDT Biologika GmbH, and Sinovac Biotech Ltd.

Key Developments:

In July 2025, Merck and Verona Pharma plc announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

In August 2024, Immunologicals Limited (IIL) has announced partnership with Central Institute of Brackishwater Aquaculture (CIBA), Chennai, an Indian Council of Agricultural Research (ICAR) Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish developed by CIBA.

Products Covered:

• M-M-R II
• PRIORIX
• Tresivac
• M-M-RvaxPro
• Other Product Types

Vaccine Types Covered:

• Standalone Vaccines
• Combination Vaccines

Route of Administrations Covered:

• Subcutaneous Injections
• Intramuscular Injections

Age Groups Covered:

• Infants (0-1 year)
• Children (1-12 years)
• Adolescents
• Adults

Distribution Channels Covered:

• Hospital Pharmacies
• Government Suppliers
• Retail Pharmacies
• NGO & International Aid Programs

End Users Covered:

• Hospitals
• Public Health Agencies
• Pediatric Clinics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Product

• 5.1 Introduction
• 5.2 M-M-R II
• 5.3 PRIORIX
• 5.4 Tresivac
• 5.5 M-M-RvaxPro
• 5.6 Other Product Types

6 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Vaccine Type

• 6.1 Introduction
• 6.2 Standalone Vaccines
• 6.3 Combination Vaccines

7 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Route of Administration

• 7.1 Introduction
• 7.2 Subcutaneous Injections
• 7.3 Intramuscular Injections

8 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Age Group

• 8.1 Introduction
• 8.2 Infants (0-1 year)
• 8.3 Children (1-12 years)
• 8.4 Adolescents
• 8.5 Adults

9 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacies
• 9.3 Government Suppliers
• 9.4 Retail Pharmacies
• 9.5 NGO & International Aid Programs

10 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Public Health Agencies
• 10.4 Pediatric Clinics
• 10.5 Other End Users

11 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Merck & Co., Inc.
• 13.2 Indian Immunologicals Ltd.
• 13.3 GlaxoSmithKline plc (GSK)
• 13.4 Meiji Seika Pharma Co., Ltd.
• 13.5 Sanofi
• 13.6 Panacea Biotec Ltd.
• 13.7 Serum Institute of India Pvt. Ltd.
• 13.8 LG Chem Ltd.
• 13.9 Bharat Biotech International Ltd.
• 13.10 Walvax Biotechnology Co., Ltd.
• 13.11 Zydus Lifesciences Ltd.
• 13.12 Mitsubishi Tanabe Pharma Corporation
• 13.13 Bio-Med Pvt. Ltd.
• 13.14 IDT Biologika GmbH
• 13.15 Sinovac Biotech Ltd.